دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Human Adult Fibroblast-like Synoviocytes and Articular Chondrocytes Exhibit Prominent Overlap in Their Transcriptomic Signatures
Kyle Jones, Marco Angelozzi, Umesh Gangishetti, Abdul Haseeb, Charles de Charleroy, Véronique Lefebvre, Pallavi Bhattaram
doi : 10.1002/acr2.11255
Volume 3, Issue 6 p. 359-370
Fibroblast-like synoviocytes (FLS) and articular chondrocytes (AC) derive from a common pool of embryonic precursor cells. They are currently believed to engage in largely distinct differentiation programs to build synovium and articular cartilage and maintain healthy tissues throughout life. We tested this hypothesis by deeply characterizing and comparing their transcriptomic attributes.
Testing the Effects of Disease-Modifying Antirheumatic Drugs on Vascular Inflammation in Rheumatoid Arthritis: Rationale and Design of the TARGET Trial
Jon T. Giles, Pamela M. Rist, Katherine P. Liao, Ahmed Tawakol, Zahi A. Fayad, Venkatesh Mani, Nina P. Paynter, Paul M. Ridker, Robert J. Glynn, Fengxin Lu, Rachel Broderick, Meredith Murray, Kathleen M. M. Vanni, Daniel H. Solomon, Joan M. Bathon
doi : 10.1002/acr2.11256
Volume 3, Issue 6 p. 371-380
Individuals with rheumatoid arthritis (RA) are at increased risk for atherosclerotic cardiovascular disease (ASCVD) events relative to the general population, potentially mediated by atherosclerotic plaques that are more inflamed and rupture prone. We sought to address whether RA immunomodulators reduce vascular inflammation, thereby reducing ASCVD risk, and whether such reduction depends on the type of immunomodulator. The TARGET (Treatments Against RA and Effect on 18-Fluorodeoxyglucose [18F-FDG] Positron Emission Tomography [PET]/Computed Tomography [CT]) trial (NCT02374021) will enroll 150 patients with RA with active disease and an inadequate response to methotrexate. Participants will be randomized to add either a tumor necrosis factor (TNF) inhibitor (etanercept or adalimumab) or sulfasalazine and hydroxychloroquine to their background methotrexate. Participants will undergo full-body 18F-FDG–labelled PET scanning at baseline and after 6 months. Efficacy and safety evaluations will occur every 6 weeks, with therapy modified in a treat-to-target approach. The primary outcome is the comparison of change in arterial inflammation in the wall of the aorta and carotid arteries between the randomized treatment groups, specifically, the change in the mean of the maximum target-to-background ratio of arterial 18F-FDG uptake in the most diseased segment of either the aorta and carotid arteries. A secondary analysis will compare the effects of achieving low disease activity or remission with those of moderate to high disease activity on vascular inflammation. The TARGET trial will test, for the first time, whether RA treatments reduce arterial inflammation and whether such reduction differs according to treatment strategy with either TNF inhibitors or a combination of nonbiologic disease-modifying antirheumatic drugs.
Social Distancing, Health Care Disruptions, Telemedicine Use, and Treatment Interruption During the COVID-19 Pandemic in Patients With or Without Autoimmune Rheumatic Disease
Michael D. George, Joshua F. Baker, Shubhasree Banerjee, Howard Busch, David Curtis, Maria I. Danila, Kelly Gavigan, Daniel Kirby, Peter A. Merkel, George Munoz, William Benjamin Nowell, Patrick Stewart, William Sunshine, Shilpa Venkatachalam, Fenglong Xie, Jeffrey R. Curtis
doi : 10.1002/acr2.11239
Volume 3, Issue 6 p. 381-389
We aimed to compare concerns, social distancing, health care disruptions, and telemedicine use in patients with autoimmune rheumatic disease (ARD) and non-ARD and to evaluate factors associated with immunomodulatory medication interruptions.
The Association of Diuretics and Proton Pump Inhibitors With Chondrocalcinosis
David T. Felson, Gabriela Rabasa, Xiaoyang Chen, Michael LaValley, S. Reza Jafarzadeh, Cora E. Lewis, James Torner, Michael C. Nevitt, Devyani Misra
doi : 10.1002/acr2.11260
Volume 3, Issue 6 p. 390-394
Hypomagnesemia increases the risk of chondrocalcinosis and calcium pyrophosphate disease. We examined whether the use of drugs that can cause hypomagnesemia, diuretics and proton pump inhibitors (PPIs), increases the risk of chondrocalcinosis.
Clinical Images: Cerebral venous sinus thrombosis as one of the initial presentations of systemic lupus erythematous
Chiao-Feng Cheng, Ko-Jen Li
doi : 10.1002/acr2.11262
Volume 3, Issue 6 p. 395-395
Foot and Ankle Problems in Patients With Rheumatoid Arthritis in 2019: Still an Important Issue
Morten Bilde Simonsen, Kim H?rslev-Petersen, Maria C. C?ster, Carsten Jensen, Ann Bremander
doi : 10.1002/acr2.11258
Volume 3, Issue 6 p. 396-402
To study the prevalence of foot pain in patients with rheumatoid arthritis (RA) and whether including a 12-joint foot count in addition to the 28-joint count (from the Disease Activity Score 28 [DAS28]) improved detection of foot or ankle pain. In addition, the association between the self-reported foot and ankle score (SEFAS), patient-reported function, and disease-specific factors was studied.
Clinical Images: Chorea in systemic lupus erythematosus: abnormal movements and ischemic lesions on magnetic resonance imaging
Fabio Andrés Torres Saavedra, Kaarem Gutiérrez, Ruth Eraso Garnica
doi : 10.1002/acr2.11264
Volume 3, Issue 6 p. 403-403
Clinical Manifestations and Long-Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America
Irena Doubelt, David Cuthbertson, Simon Carette, Sharon A. Chung, Lindsy J. Forbess, Nader A. Khalidi, Curry L. Koening, Carol Langford, Carol A. McAlear, Larry W. Moreland, Paul A. Monach, Philip Seo, Ulrich Specks, Robert F. Spiera, Jason M. Springer, Antoine G. Sreih, Kenneth J. Warrington, Peter A. Merkel, Christian Pagnoux, for the Vasculitis Clinical Research Consortium
doi : 10.1002/acr2.11263
Volume 3, Issue 6 p. 404-412
To describe clinical manifestations and outcomes in patients with eosinophilic granulomatosis with polyangiitis (EGPA) in North America.
Repeated Spinal Mobility Measures and Their Association With Radiographic Damage in Ankylosing Spondylitis
Mark C. Hwang, MinJae Lee, Lianne S. Gensler, Michael M. Ward, Matthew A. Brown, Thomas J. Learch, Amirali Tahanan, Mohammad H. Rahbar, Mariko Ishimori, Michael H. Weisman, John D. Reveille, the PSOAS Study Investigators
doi : 10.1002/acr2.11261
Volume 3, Issue 6 p. 413-421
We sought to explore the relationship between changes in repeated mobility measures and spinal structural progression in patients with ankylosing spondylitis (AS) over time.
Exploring the Role of Antinuclear Antibody Positivity in the Diagnosis, Treatment, and Health Outcomes of Patients With Rheumatoid Arthritis
Sujaytha S. Paknikar, Cynthia S. Crowson, John M. Davis, Uma Thanarajasingam
doi : 10.1002/acr2.11271
Volume 3, Issue 6 p. 422-426
The objective of this study was to describe differences in the clinical course of patients with rheumatoid arthritis (RA) who are antinuclear antibody (ANA)–positive compared with those who are ANA-negative.
